Just like patients with cardiovascular problems, patients who have had a cerebral infarction or TIA are advised to aim for LDL-cholesterol values below 1.8 mmol/L. At the time when this recommendation was published, there had been insufficient research to substantiate this advice for this target group. A new study offers some substantiation, but is subject to various limitations.
- New research finds a lower risk for a composite endpoint of cardiovascular complications at lower target values for LDL-cholesterol, but this study has too many limitations to enable a firm conclusion to be drawn from the findings.
- Previous research shows that statins are only moderately effective in secondary prevention after a TIA or cerebral infarction.
- There is insufficient evidence for a lower target value for LDL-cholesterol in secondary prevention for patients with a history of TIA or cerebral infarction.
- Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Béjot Y, et al. Treat Stroke to Target Investigators. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med. 2020 Jan 2;382(1):9. doi: 10.1056/NEJMoa1910355.
- Wechsler LR. Statins and Stroke - It's Complicated. N Engl J Med. 2020 Jan 2;382(1):81-82. doi: 10.1056/NEJMe1914757.
- Paraskevas KI. LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med. 2020 Apr 9;382(15):1480. doi: 10.1056/NEJMc2001195.
- Amarenco P, Kim JS; Executive Committee of the Treat Stroke to Target Trial. LDL Cholesterol Targets after Ischemic Stroke. Reply. N Engl J Med. 2020 Apr 9;382(15):1480-1481. doi: 10.1056/NEJMc2001195.
- Federatie Medisch Specialisten. Richtlijn Herseninfarct en hersenbloeding 1-5-2019. Available from: https://richtlijnendatabase.nl/richtlijn/herseninfarct_en_hersenbloeding/secundaire_preventie_na_tia_of_herseninfarct/medicamenteuze_interventies_na_herseninfarct/streefwaarden_ldl-_cholesterolgehalte.html#tab-content-substantiation. Accessed 22-10-2020.
- Collins R, Armitage J, Parish S, Sleight P, Peto R. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004 Mar 6;363(9411):757-67. doi: 10.1016/S0140-6736(04)15690-0.
- Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006 Aug 10;355(6):549-59. doi: 10.1056/NEJMoa061894. Erratum in: N Engl J Med. 2018 Jun 13;:null. PMID: 16899775.
- Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5.
- Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke. 2008 Feb;39(2):497-502. doi: 10.1161/STROKEAHA.107.488791.
- NHG-Standaard Cardiovasculair risicomanagement versie 4.0. Juni 2019. Available from: https://richtlijnen.nhg.org/. Accessed 22-10-2020.